German Hernandez, MD
Nephrology · El Paso, TXNPI 1154367704
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,024,458 of the $1,312,385 with a category attached, or 78.1%. It is spread thinly across 45 manufacturers, the largest accounting for just 23.1%. Reporting peaked in 2023 at $297,348 and has fallen 58.0% since, to $125,001 in 2025. Among nephrology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,348 payments — averaging $558.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aurinia Pharma U.S., Inc.$303K
- Bayer$217K
- AstraZeneca$169K
- Otsuka America Pharmaceutical, Inc.$164K
- Calliditas Therapeutics US Inc.$103K
- Akebia Therapeutics Inc$87K
- plus $269K from 39 others
Across 1,344 payments — averaging $6203.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$2.6M
- Astrazeneca UK Limited$2.2M
- AstraZeneca$1.4M
- Bayer$406K
- Akebia Therapeutics Inc$397K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$369K
- plus $1.1M from 22 others
What the payments were for
- Consulting fees$83,3466%
- Speaking & faculty fees$1,024,45878%
- Travel & lodging$161,76712%
- Food & beverage$42,1833%
- Education$6310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,312,385 in reported general payments places this provider in the 95th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 527 | $645,260 |
| LupkynisVoclosporin | 24 | $314,130 |
| JardianceEmpagliflozin | 175 | $269,298 |
| KerendiaFinerenone | 203 | $268,621 |
| OzempicSemaglutide | 112 | $147,767 |
| XphozahTenapanor Hcl | 28 | $87,886 |
| VeltassaPatiromer Calcium Sorbitex | 58 | $79,945 |
| VelphoroSucroferric Oxyhydroxide | 17 | $54,397 |
| MounjaroTirzepatide | 45 | $54,275 |
| RybelsusSemaglutide | 25 | $52,266 |
| LokelmaSodium Zirconium Cyclosilicate | 50 | $47,963 |
| EntrestoSacubitril/Valsartan | 22 | $35,241 |
| TrulicityDulaglutide | 21 | $30,238 |
| Sevelamer Carbonate | 43 | $18,273 |
| RayaldeeCalcifediol | 12 | $16,416 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $169,285 | $693,223577 claims |
| Aurinia Pharma U.S., Inc.Lupkynis | $303,215 | $314,13024 claims |
| Boehringer IngelheimJardiance | $25,081 | $269,298175 claims |
| BayerKerendia | $217,245 | $268,621203 claims |
| Novo NordiskOzempic, Rybelsus | $783 | $200,033137 claims |
| Lilly USA, LLCMounjaro, Trulicity | $16,070 | $84,51266 claims |
| Fresenius USA Marketing, Inc.Velphoro | $250 | $54,39717 claims |
| NovartisEntresto | $748 | $35,24122 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $630 | $16,41612 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $15 | $87948 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,070 nephrology providers in Texas.
Other nephrology in El Paso
- Abdul AbdellatifWebster$2.1M
- Ankit MehtaDallas$1.1M
- Biff PalmerDallas$867K
- Gates ColbertDallas$828K
- Sreedhar MandayamHouston$752K
- Luis VelezSan Antonio$505K
- Anand ReddyOdessa$469K
- Christopher KwohHouston$467K
- Wolfgang WinkelmayerHouston$462K
- Saravanan BalamuthusamyFort Worth$435K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.